Ocular Therapeutix (OCUL) Upgraded at ValuEngine
ValuEngine upgraded shares of Ocular Therapeutix (NASDAQ:OCUL) from a sell rating to a hold rating in a report issued on Thursday morning.
OCUL has been the subject of a number of other reports. BidaskClub downgraded Ocular Therapeutix from a hold rating to a sell rating in a research report on Wednesday, July 4th. HC Wainwright set a $10.00 price objective on Ocular Therapeutix and gave the stock a buy rating in a research report on Monday, July 2nd. Zacks Investment Research downgraded Ocular Therapeutix from a buy rating to a hold rating in a research report on Wednesday, July 25th. Cantor Fitzgerald set a $22.00 price objective on Ocular Therapeutix and gave the stock a buy rating in a research report on Tuesday, August 7th. Finally, Piper Jaffray Companies assumed coverage on Ocular Therapeutix in a research report on Thursday, September 6th. They set an overweight rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $12.00.
NASDAQ OCUL opened at $6.45 on Thursday. Ocular Therapeutix has a 52 week low of $3.30 and a 52 week high of $8.28. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.91 and a current ratio of 4.92.
In other Ocular Therapeutix news, CEO Antony C. Mattessich acquired 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 20th. The stock was purchased at an average cost of $5.95 per share, with a total value of $119,000.00. Following the transaction, the chief executive officer now owns 57,900 shares of the company’s stock, valued at $344,505. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Donald Notman acquired 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were acquired at an average cost of $6.29 per share, with a total value of $78,625.00. Following the completion of the transaction, the chief financial officer now directly owns 17,300 shares in the company, valued at approximately $108,817. The disclosure for this purchase can be found here. Insiders have purchased a total of 49,400 shares of company stock valued at $302,912 over the last three months. Corporate insiders own 15.90% of the company’s stock.
Large investors have recently modified their holdings of the stock. Opaleye Management Inc. acquired a new position in Ocular Therapeutix in the 2nd quarter valued at about $7,499,000. Deltec Asset Management LLC grew its position in Ocular Therapeutix by 173.6% in the 1st quarter. Deltec Asset Management LLC now owns 586,239 shares of the biopharmaceutical company’s stock valued at $3,816,000 after acquiring an additional 372,000 shares in the last quarter. BlackRock Inc. grew its position in Ocular Therapeutix by 19.6% in the 1st quarter. BlackRock Inc. now owns 1,696,612 shares of the biopharmaceutical company’s stock valued at $11,046,000 after acquiring an additional 278,035 shares in the last quarter. Northern Trust Corp grew its position in Ocular Therapeutix by 24.1% in the 1st quarter. Northern Trust Corp now owns 324,526 shares of the biopharmaceutical company’s stock valued at $2,112,000 after acquiring an additional 62,993 shares in the last quarter. Finally, Nottingham Advisors Inc. grew its position in Ocular Therapeutix by 30.5% in the 2nd quarter. Nottingham Advisors Inc. now owns 191,766 shares of the biopharmaceutical company’s stock valued at $1,294,000 after acquiring an additional 44,820 shares in the last quarter. 56.65% of the stock is owned by hedge funds and other institutional investors.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.